found in eyes with uncomplicated retinal detachments without intraocular fibrosis (360±91 pM [SEMI). Using an in vitro assay, 84-100% of the TGF-,B activity could be blocked with specific antibodies against TGF-fl2, whereas only 10-21% could be blocked by specific antibodies against TGF-,61.
Introduction
The role of peptide growth factors in wound healing and fibrosis has recently received particular attention. Platelet-derived growth factor (PDGF),I fibroblast growth factor (FGF), vitreoretinopathy; TGF-fl, transforming growth factor- (3. and transforming growth factor-# (TGF-fl) have recently been shown to have potential roles in the fibrotic process. PDGF is released from the a-granules ofplatelets, as well as from monocytes, and is a chemoattractant and a mitogen for fibroblasts (1) . FGF is also a mitogen for fibroblasts and induces an increase in DNA content when introduced into porous subcutaneous chambers (2) . TGF-# appears to have a particularly important role in the fibrotic process. This peptide is found in high concentrations in the a-granules ofplatelets (3) and is also secreted by activated T lymphocytes (4) and macrophages (5) . Like PDGF, it is also chemotactic for both monocytes (6) and fibroblasts (7) . When injected subcutaneously in newborn mice, it causes a rapid fibrotic and angiogenic response at the site of injection (8) ; the new tissue formed is essentially granulation tissue (8, 9) . In vitro, TGF-,3 has been shown to regulate both synthesis (8, 9) and degradation of matrix proteins, leading to their increased accumulation (10) . TGF-f3 has recently been found to exist in two distinct molecular forms, TGF-j,3
and TGF-32 (10, 11) . Current data suggest that there may be separate receptors for TGF-f3, and TGF-,32, some of which are cross-reactive (10, 1 1). However, the relative roles of TGF-f31
and TGF-fl2 in the fibrotic process have not yet been determined.
Although laboratory studies have shown that both PDGF and TGF-3 can enhance fibrosis, little clinical evidence is yet available correlating the levels of these growth factors with the degree of fibrosis in a clinical setting. An important recent study has shown that PDGF is secreted in exaggerated amounts by alveolar macrophages from patients with idiopathic pulmonary fibrosis (12) , demonstrating a possible association between a peptide growth factor and a disease process involving pathologic fibrosis, but the actual levels within the fibrotic pulmonary tissue were not determined. Proliferative vitreoretinopathy (PVR), the most common cause of failure in retinal reattachment surgery, is an ocular disorder characterized by excessive fibrosis on both surfaces of the retina and within the vitreous cavity (I13-17). Quantification of TGF- (3 As has been found for TGF-,3 secreted into medium by cells (23, 24) , as well as TGF-/3 released from platelets (25) , and in wound fluid (26) , -87% of the TGF-# in intraocular fluid was latent. The degree of latency was not a function of the disease state of the patients in this study. For this reason, samples were activated by acidification with 150 mM HCI for 30 min followed by reneutralization prior to assay (24) . A competitive radioreceptor binding assay using A549 human lung carcinoma cells (24) and an assay measuring formation ofcolonies ofNRK cells in soft agar in the presence of epidermal growth factor (27) were carried out exactly as previously described. An assay of the inhibition by TGF-(1 of the growth of CCL64 mink lung epithelial cells (28, 29) was modified as follows: cells were seeded into 24-well multidishes at a density of 5 Antibodies to TGF-f3, and TGF-[2 Turkeys were injected with uncoupled porcine TGF-,B1 orTGF-#2 (100 Mg) in Freund's complete adjuvant and boosted every 2 wk with equivalent amounts of TGF-# in incomplete Freund's adjuvant. Antisera were titered in an ELISA and measured for blocking activity in either a radioreceptor binding assay or the growth inhibition assay described above.
TGF-PB was purified from human platelets as previously described (33), followed by a final purification step using high-performance liquid chromatography. The peptide was quantitated by amino acid analysis. TGF-(32 from porcine platelets (11) was purchased from R&D Systems, Minneapolis, MN.
Effect ofintravitreal injection of TGF-f3, on intraocular fibrosis Pigmented dutch belted rabbits weighing 5-8 lb (2.3-3.6 kg) were anesthetized by intramuscular injection ofketamine and xylazine. The pupils were dilated with 1% tropicamide and one eye was gently prolapsed and draped. An 8-ml transcleral incision was made 1-2 ml posterior to the limbus. The wound was closed with multiple interrupted 8-0 black silk sutures. After wound closure, 0.2 ml ofone ofthe following solutions was injected into the midvitreous cavity via a 30-gauge needle 1-2 ml posterior to the limbus in the superotemporal quadrant. The following solutions were injected:
Control. Eagle's minimum essential medium with 0.1 mg/ml BSA. Group 1. Eagle's minimum essential medium with 0.1 mg/ml BSA and 100 ng of TGF-flI. The same injections were repeated after 24 
Results
The concentration of total TGF-fl-like activity in the vitreous aspirates was determined using the competitive radioreceptor binding assay and was calculated by comparison of dilution curves of aspirates with that of a standard curve generated using purified TGF-3,1 ( Fig. 1 and Table I 2). These levels represent the sum of both intrinsically active and latent TGF-,B, since samples were acidified before assay, a treatment known to activate latent TGF-,B (23, 24) . Vitreous aspirates assayed without acid pretreatment had 9-13% of the activity found following acid treatment. A comparable degree of enhancement of TGF-# activity has been observed for medium conditioned by many different human and rodent cell lines (23, 24 Table I ). Samples from eyes with PVR were grouped according to disease severity as described in the Methods section. Analysis ofTGF-(B levels in these groups revealed that as clinical disease progressed from mild to moderate to severe, total TGF-3 levels likewise increased (Fig. 3) . Total TGF-j3 levels of these four groups were analyzed collectively with the Kruskal-Wallis nonparametric one-way analysis of variance which showed that the groups are different (P < 0.001), with the mean ranks ofTGF-(3 levels ofeach group increasing monotonically, paralleling the increase in clinical severity seen among the four groups (Table II) . Total TGF-i3 levels of the groups were then analyzed independently with each of the other groups using the Wilcoxon rank sum test. This analysis demonstrated that total TGF-# levels of the group with severe PVR are different from all other groups (P < 0.001), and the group with moderate PVR is different from the group with uncomplicated RD (P < 0.02). These data demonstrate that as the severity ofPVR increased, intraocular levels of TGF-3 from these same eyes likewise increased.
TGF-beta is also a potent inhibitor of the growth of CCL 64 cells (28, 29) . As further confirmation of the levels of total TGF-3 detected by the radioreceptor binding assay, several intraocular fluid samples were tested for growth inhibition of CCL 64 cells and colony formation of NRK cells in soft agar.
Values of total TGF-(# in the specimens as determined by the radioreceptor binding assay correlated with values determined by these assays (Fig. 4 A) . This finding confirms the presence of TGF-,3 in the intraocular fluid specimens, and it also demonstrates that the samples contain no significant concentrations of mitogens which would oppose the inhibitory action of TGF-3 in the growth inhibition assay.
In order to determine the type of TGF-,B in the vitreous aspirates, type-specific polyclonal antibodies raised in turkeys against either porcine TGF-l,1 or TGF-,32 were used in an attempt to block the growth inhibitory activity of the samples.
As shown in Fig. 4 Fig. 4 B). Quantitation of the TGF-# levels of intraocular fluid samples by competitive radioreceptor assay, as described in Fig. 1 Figure 3 . Quantitation of the TGF-# levels of intraocular fluid samples by competitive radioreceptor assay, as described in Fig. 1 TGF-t,1 or TGF-02, 2.8 pM; patient 35, 32 Ml/ml; patient 4, 4.3 ,l/ml; patient 42, 1.8 Il/ml; patient 11, 0.9 zd/ml; serum-free medium conditioned by cultured retinal pigment epithelial cells, 9 AI/ml.
These findings also may shed some light on the source of TGF-# within eyes with PVR. During retinal detachment surgery, various forms of retinopexy are applied to the choroid and retina in order to induce a localized scar in the region of a retinal tear. It has been found that all forms of retinopexy including cryotherapy, photocoagulation, and diatherapy cause significant breakdown of the blood-ocular barriers, thereby allowing serum components access to the intraocular space (31) . It has been postulated that these serum components may play a role in inducing the resultant fibrosis (31) . In the case of TGF-fl, the majority of the growth factor in the intraocular fluid has been found to be type 2 and, therefore, not serum derived. The smaller amount of TGF-#, may indeed be derived from serum. This suggests that there may be an intraocular source of TGF-(32. We have recently found that the retinal pigment epithelial cells can synthesize and secrete TGF-,B2 in addition to TGF-#i) in vitro (Connor, T. B., A. B.
Roberts, M. B. Sporn, and B. M. Glaser, manuscript in preparation). These findings suggest that the retinal pigment epithelium may play a central role in the development of fibrosis following retinal detachment surgery as has been previously postulated.
Since TGF-t)2 levels are elevated in the vitreous cavity of eyes with increased intraocular fibrosis, we questioned whether intravitreal injections of TGF-,3 might induce intraocular fibrosis in an animal model. The amount of human TGF-#82 available to us for this study was limited. However, since no functional differences have yet been found between TGF-3,1 and TGF-,B2, we have performed these experiments using human TGF-#,3. We found that TGF-lh alone did not induce a significant increase in intravitreal fibrosis when injected into the vitreous cavity. However, TGF-l,1 combined with FN did result in a significant increase in intravitreal fibrosis and resultant traction retinal detachment while FN alone had no effect. Interestingly, FN has been found in increased levels in human eyes with intraocular fibrosis associated with PVR (32) . In addition, TGF-fl, but not PDGF nor FGF, has recently been shown to enhance the ability of fibroblasts to contract a collagen matrix in vitro (33) . The stimulation of cell-mediated collagen gel contraction was greatly enhanced in the presence of serum (33) . It may be that the ability of FN to enhance the ability of intravitreal TGF-#,1 to induce vitreous gel contraction and resultant traction retinal detachment is related to the enhancement ofgel contraction in vitro by serum components such as FN. Experiments are currently underway to determine if FN in serum accounts for the latter effect.
Recent studies utilizing both bioassays and immunoassays have failed to demonstrate detectable levels of basic FGF in vitreous aspirates from eyes with PVR or uncomplicated retinal detachments (Snyder, M., T. B. Connor, and B. M. Glaser, manuscript in preparation). Preliminary studies have likewise so far not revealed an association between levels of PDGF in eyes with PVR and the severity of the disease (Grotendorst, G. R., T. B. Connor, and B. M. Glaser, unpublished data).
Thus, in this disease entity, levels of TGF-42 are associated with the severity of the fibrotic process, whereas FGF and PDGF may not be similarly associated. The ability of TGF-,3 to attract fibroblasts and monocytes (6, 7) as well as its unique ability to enhance the synthesis of extracellular matrix components (8, 9) and stimulate cell-mediated contraction of collagen gels may set up a cycle of events that promotes the successive formation of fibrotic tissue in this disease process. The final determination ofthe role ofTGF-( in this disease process awaits the ability to block its activity and assess if this can 
